HC Wainwright Brokers Decrease Earnings Estimates for EYPT

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities researchers at HC Wainwright dropped their Q1 2026 EPS estimates for shares of Eyepoint Pharmaceuticals in a research note issued on Thursday, March 5th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their prior estimate of ($0.65). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.93) EPS.

Several other research firms have also recently weighed in on EYPT. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Citigroup upped their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Chardan Capital raised their price objective on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $32.20.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $15.67 on Monday. The stock’s 50-day moving average is $15.61 and its 200-day moving average is $14.42. The company has a market cap of $1.31 billion, a P/E ratio of -4.96 and a beta of 1.72. Eyepoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%.The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.01 million.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its stake in shares of Eyepoint Pharmaceuticals by 16.6% in the fourth quarter. Invesco Ltd. now owns 339,004 shares of the company’s stock valued at $6,194,000 after purchasing an additional 48,186 shares in the last quarter. Virtus Investment Advisers LLC boosted its stake in Eyepoint Pharmaceuticals by 29.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,638 shares of the company’s stock worth $304,000 after buying an additional 3,795 shares in the last quarter. Susquehanna Portfolio Strategies LLC boosted its stake in Eyepoint Pharmaceuticals by 22.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 74,944 shares of the company’s stock worth $1,369,000 after buying an additional 13,750 shares in the last quarter. Suvretta Capital Management LLC increased its holdings in Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after buying an additional 1,634,970 shares during the period. Finally, Orbimed Advisors LLC increased its holdings in Eyepoint Pharmaceuticals by 37.4% in the 4th quarter. Orbimed Advisors LLC now owns 2,468,314 shares of the company’s stock valued at $45,096,000 after buying an additional 672,314 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Insider Transactions at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.46% of the stock is owned by corporate insiders.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.